FFA
KROS icon

Farther Finance Advisors’s Keros Therapeutics KROS Stock Holding History

Farther Finance Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71K Buy
252
+166
+193% +$1.85K ﹤0.01% 5057
2026
Q1 		$1K Sell
86
-536
-86% -$8.28K ﹤0.01% 5105
2025
Q4 		$12.7K Sell
622
-2,352
-79% -$41.3K ﹤0.01% 3757
2025
Q3 		$47K Buy
+2,974
New +$43.9K ﹤0.01% 2472
2025
Q1 		– Sell
-1
Closed -$16 – 4347
2024
Q4 		$16 Sell
1
-1
-50% -$52 ﹤0.01% 3945
2024
Q3 		$116 Buy
2
+1
+100% +$49 ﹤0.01% 3757
2024
Q2 		$44 Hold
1
– – ﹤0.01% 3706
2024
Q1 		$67 Hold
1
– – ﹤0.01% 3437
2023
Q4 		$40 Buy
+1
New +$31 ﹤0.01% 3405

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Farther Finance Advisors's KROS Position: Q2 2026 in Review

Farther Finance Advisors increased its Keros Therapeutics (KROS) stake by 193% in Q2 2026, buying an estimated $1.85K and bringing the position to 252 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #5057.

Farther Finance Advisors first reported a position in KROS in Q4 2023 and has held it in 9 quarters since. The position peaked at $47K in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Farther Finance Advisors held 252 shares of Keros Therapeutics worth $2.71K as of Q2 2026.
  • Farther Finance Advisors bought 166 Keros Therapeutics shares in Q2 2026, an estimated $1.85K.
  • Keros Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5057 holding.
  • Farther Finance Advisors first reported a position in Keros Therapeutics in Q4 2023 and has held it in 9 quarters since.
  • Farther Finance Advisors's Keros Therapeutics position peaked at $47K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.